Skip to main content

Research Repository

Advanced Search

All Outputs (211)

Cough Reflex Hypersensitivity as a Key Treatable Trait (2024)
Journal Article
Song, W. J., Manian, D. V., Kim, Y., Zhang, M., & Morice, A. H. (in press). Cough Reflex Hypersensitivity as a Key Treatable Trait. The journal of allergy and clinical immunology. In practice, https://doi.org/10.1016/j.jaip.2024.10.046

Cough reflex hypersensitivity is emerging as a key treatable trait in chronic cough and other cough-associated respiratory conditions. This review examines the neurological basis of cough, highlighting the complex interplay between peripheral and cen... Read More about Cough Reflex Hypersensitivity as a Key Treatable Trait.

Current and emerging opioids for the treatment of chronic cough: a mini review (2024)
Journal Article
Zhang, M., & Morice, A. H. (online). Current and emerging opioids for the treatment of chronic cough: a mini review. Expert Opinion on Pharmacotherapy, https://doi.org/10.1080/14656566.2024.2418983

Introduction: Chronic cough has increasingly been recognized as a distinct clinical entity that affects a significant portion of the global population. Despite advancements in understanding its pathophysiology, treatment options remain limited. Opioi... Read More about Current and emerging opioids for the treatment of chronic cough: a mini review.

Practice review: Pharmacological management of severe chronic breathlessness in adults with advanced life-limiting diseases (2024)
Journal Article
Simon, S. T., Higginson, I. J., Bausewein, C., Jolley, C. J., Bajwah, S., Maddocks, M., Wilharm, C., Oluyase, A. O., & Pralong, A. (online). Practice review: Pharmacological management of severe chronic breathlessness in adults with advanced life-limiting diseases. Palliative medicine, https://doi.org/10.1177/02692163241270945

Background: Severe and refractory chronic breathlessness is a common and burdensome symptom in patients with advanced life-limiting disease. Its clinical management is challenging because of the lack of effective interventions. Aim: To provide practi... Read More about Practice review: Pharmacological management of severe chronic breathlessness in adults with advanced life-limiting diseases.

Decoding the impact of the placebo response in clinical trials for chronic cough (2024)
Journal Article
Zhang, M., Zhang, B., & Morice, A. H. (2024). Decoding the impact of the placebo response in clinical trials for chronic cough. ERJ Open Research, 10(5), Article 00335-2024. https://doi.org/10.1183/23120541.00335-2024

Chronic cough is a prevalent and challenging condition, with limited treatment options available. The interpretation of clinical trial results for antitussive drugs is complicated by the presence of the placebo response, which can confound outcomes a... Read More about Decoding the impact of the placebo response in clinical trials for chronic cough.

Correction to: Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (npj Primary Care Respiratory Medicine, (2024), 34, 1, (6), 10.1038/s41533-024-00363-0) (2024)
Journal Article
Crooks, M. G., Cummings, H., Morice, A. H., Sykes, D., Brooks, S., Jackson, A., & Xu, Y. (2024). Correction to: Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (npj Primary Care Respiratory Medicine, (2024), 34, 1, (6), 10.1038/s41533-024-00363-0). NPJ Primary Care Respiratory Medicine, 34(1), Article 19. https://doi.org/10.1038/s41533-024-00376-9

Correction to: npj Primary Care Respiratory Medicine34, 6 (2024) https://doi.org/10.1038/s41533-024-00363-0, published online 29 April 2024 In this article the Table 2 columns were incorrectly structured. The original article has been corrected.

Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial (2024)
Journal Article
Devereux, G., Cotton, S., Nath, M., McMeekin, N., Campbell, K., Chaudhuri, R., Choudhury, G., De Soyza, A., Fielding, S., Gompertz, S., Haughney, J., Lee, A. J., MacLennan, G., Morice, A., Norrie, J., Price, D., Short, P., Vestbo, J., Walker, P., Wedzicha, J., …Lipworth, B. J. (2024). Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial. Journal of the American Medical Association, https://doi.org/10.1001/jama.2024.8771

Importance: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Observational studies report that β-blocker use may be associated with reduced risk of COPD exacerbations. However, a recent trial repor... Read More about Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial.

Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (2024)
Journal Article
Crooks, M. G., Cummings, H., Morice, A. H., Sykes, D., Brooks, S., Jackson, A., & Xu, Y. (2024). Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites. NPJ Primary Care Respiratory Medicine, 34(1), Article 6. https://doi.org/10.1038/s41533-024-00363-0

Short-acting beta-agonist (SABA) over-use in asthma is harmful for patients and the environment. The Investment and Impact Fund (IIF) 2022/2023 financially rewarded English primary care networks that achieved specific targets, including reducing SABA... Read More about Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites.

The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies (2024)
Journal Article
Sykes, D. L., Mason, P., Rahunathan, N., Hart, S. P., Morice, A. H., & Crooks, M. G. (2024). The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies. Lung, https://doi.org/10.1007/s00408-024-00729-8

Introduction: Azithromycin is an effective treatment for various respiratory conditions but its effect on cough is poorly understood. We synthesised data from randomised controlled trials (RCTs) and noncomparative studies (NCT) examining its effect o... Read More about The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies.

Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men (2024)
Journal Article
Friedrich, C., Singh, D., Francke, K., Klein, S., Hetzel, T., Zolk, O., Gashaw, I., Scheerans, C., & Morice, A. (2024). Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men. British Journal of Clinical Pharmacology, https://doi.org/10.1111/bcp.16091

Aims: We report on investigations exploring the P2X3-receptor antagonist filapixant's effect on taste perception and cough-reflex sensitivity and describe its pharmacokinetics, including its CYP3A4-interaction potential. Methods: In a randomized, pla... Read More about Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men.

Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi study (2023)
Journal Article
Song, W. J., Dupont, L., Birring, S. S., Chung, K. F., Dąbrowska, M., Dicpinigaitis, P., Ribas, C. D., Fontana, G., Gibson, P. G., Guilleminault, L., Hull, J. H., Idzko, M., Kardos, P., Kim, H. J., Lai, K., Lavorini, F., Millqvist, E., Morice, A. H., Niimi, A., Parker, S. M., …McGarvey, L. P. (2023). Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi study. ERJ Open Research, 9(6), Article 00618-2023. https://doi.org/10.1183/23120541.00618-2023

Background Current guidelines on the management of chronic cough do not provide recommendations for the operation of specialist cough clinics. The objective of the present study was to develop expert consensus on goals and standard procedures for spe... Read More about Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi study.

New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study (2023)
Journal Article
Zhang, M., Morice, A. H., Si, F., Zhang, L., Chen, Q., Wang, S., Zhu, Y., Xu, X., Yu, L., & Qiu, Z. (2023). New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study. Allergy Asthma and Immunology Research, 15(6), 795-811. https://doi.org/10.4168/aair.2023.15.6.795

Purpose: Only limited studies have depicted the unique features and management of refractory chronic cough (RCC) and unexplained chronic cough (UCC). These led to the initiation of this study, which reported the demographic characteristics, manifesta... Read More about New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study.

Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis (2023)
Journal Article
Zheng, Z., Huang, J., Xiang, Z., Wu, T., Lan, X., Xie, S., Lin, Z., Tang, K., Morice, A., Li, S., Song, W. J., & Chen, R. (2023). Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis. EClinicalMedicine, 62, Article 102100. https://doi.org/10.1016/j.eclinm.2023.102100

Background: Refractory chronic cough (RCC) has a significant impact on patient's health-related quality of life and represents a challenge in clinical management. However, the optimal treatment for RCC remains controversial. This study aimed to inves... Read More about Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis.

Burden of chronic cough in the UK: results from the 2018 National Health and Wellness Survey (2023)
Journal Article
McGarvey, L., Morice, A. H., Martin, A., Li, V. W., Doane, M. J., Urdaneta, E., Schelfhout, J., Ding, H., & Fonseca, E. (2023). Burden of chronic cough in the UK: results from the 2018 National Health and Wellness Survey. ERJ Open Research, 9(4), Article 00157-2023. https://doi.org/10.1183/23120541.00157-2023

Background Chronic cough, defined as daily cough for at least 8 weeks, negatively affects quality of life and work productivity and increases healthcare resource utilisation. We aimed to determine the prevalence and burden of chronic cough in the UK.... Read More about Burden of chronic cough in the UK: results from the 2018 National Health and Wellness Survey.

Reply to Weinberger (2023)
Journal Article
Birring, S. S., Morice, A. H., Dicpinigaitis, P. V., McGarvey, L. P., Pavord, I. D., Green, S. A., Philip, G., & Smith, J. A. (2023). Reply to Weinberger. American Journal of Respiratory and Critical Care Medicine, 207(12), 1650-1651. https://doi.org/10.1164/rccm.202304-0709LE

Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study (2023)
Journal Article
Dicpinigaitis, P. V., Morice, A. H., Smith, J. A., Sher, M. R., Vaezi, M., Guilleminault, L., Niimi, A., Gude, K., Krahn, U., Saarinen, R., Pires, P. V., Wosnitza, M., & McGarvey, L. (2023). Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study. Lung, 201, Article 255-266. https://doi.org/10.1007/s00408-023-00621-x

Introduction: The PAGANINI study evaluated the efficacy and safety of the selective P2X3 antagonist eliapixant in patients with refractory chronic cough (RCC). Methods: PAGANINI was a randomized, double-blind, parallel-group, placebo-controlled, mult... Read More about Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study.